Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
Abstract In the last months, conflicting evidence on a possible association between the use of semaglutide and incident nonarteritic anterior ischemic optic neuropathy (NAION) has emerged. A recently published study, which evaluated all patients with type 2 diabetes in Denmark, has shown with robust...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-024-00622-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585485041532928 |
|---|---|
| author | Fernando K. Malerbi Marcello C. Bertoluci |
| author_facet | Fernando K. Malerbi Marcello C. Bertoluci |
| author_sort | Fernando K. Malerbi |
| collection | DOAJ |
| description | Abstract In the last months, conflicting evidence on a possible association between the use of semaglutide and incident nonarteritic anterior ischemic optic neuropathy (NAION) has emerged. A recently published study, which evaluated all patients with type 2 diabetes in Denmark, has shown with robustness that once-weekly semaglutide doubles the five-year risk of NAION. In this comment, the new evidence is discussed, along with practical implications for type 2 diabetes patients. The possibility of ophthalmological evaluation regarding optic disc morphology is suggested, before initiation of semaglutide treatment or, for those patients already under treatment, during a follow-up ophthalmological visit. If a disc-at-risk pattern is detected, such information could be brought to the attention of the attending clinician involved with diabetes control and discussed with patients for a shared decision-making approach. A new risk-benefit discussion weighing the undoubted benefits of semaglutide in reducing cardiovascular mortality and cardiovascular events, heart failure hospitalization, and renal protection must be started and carefully balanced against a rare but devastating condition such as NAION. |
| format | Article |
| id | doaj-art-3b543ac74b6c4087961f72fc53a0fb2b |
| institution | Kabale University |
| issn | 2056-9920 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal of Retina and Vitreous |
| spelling | doaj-art-3b543ac74b6c4087961f72fc53a0fb2b2025-01-26T12:46:35ZengBMCInternational Journal of Retina and Vitreous2056-99202025-01-011111310.1186/s40942-024-00622-9Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathyFernando K. Malerbi0Marcello C. Bertoluci1Federal University of São PauloBrazilian Diabetes SocietyAbstract In the last months, conflicting evidence on a possible association between the use of semaglutide and incident nonarteritic anterior ischemic optic neuropathy (NAION) has emerged. A recently published study, which evaluated all patients with type 2 diabetes in Denmark, has shown with robustness that once-weekly semaglutide doubles the five-year risk of NAION. In this comment, the new evidence is discussed, along with practical implications for type 2 diabetes patients. The possibility of ophthalmological evaluation regarding optic disc morphology is suggested, before initiation of semaglutide treatment or, for those patients already under treatment, during a follow-up ophthalmological visit. If a disc-at-risk pattern is detected, such information could be brought to the attention of the attending clinician involved with diabetes control and discussed with patients for a shared decision-making approach. A new risk-benefit discussion weighing the undoubted benefits of semaglutide in reducing cardiovascular mortality and cardiovascular events, heart failure hospitalization, and renal protection must be started and carefully balanced against a rare but devastating condition such as NAION.https://doi.org/10.1186/s40942-024-00622-9Type 2 diabetesSemaglutideNonarteritic anterior ischemic optic neuropathy |
| spellingShingle | Fernando K. Malerbi Marcello C. Bertoluci Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy International Journal of Retina and Vitreous Type 2 diabetes Semaglutide Nonarteritic anterior ischemic optic neuropathy |
| title | Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy |
| title_full | Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy |
| title_fullStr | Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy |
| title_full_unstemmed | Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy |
| title_short | Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy |
| title_sort | semaglutide type 2 diabetes and the risk of nonarteritic anterior ischemic optic neuropathy |
| topic | Type 2 diabetes Semaglutide Nonarteritic anterior ischemic optic neuropathy |
| url | https://doi.org/10.1186/s40942-024-00622-9 |
| work_keys_str_mv | AT fernandokmalerbi semaglutidetype2diabetesandtheriskofnonarteriticanteriorischemicopticneuropathy AT marcellocbertoluci semaglutidetype2diabetesandtheriskofnonarteriticanteriorischemicopticneuropathy |